BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 12503212)

  • 1. Prognostic value of p53 overexpression in bladder tumors treated with Bacillus Calmette-Guerin.
    Peyromaure M; Ravery V
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):667-70. PubMed ID: 12503212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy.
    Pfister C; Flaman JM; Dunet F; Grise P; Frebourg T
    J Urol; 1999 Jul; 162(1):69-73. PubMed ID: 10379742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
    Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
    Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors.
    Pages F; Flam TA; Vieillefond A; Molinie V; Abeille X; Lazar V; Bressac-de Paillerets B; Mosseri V; Zerbib M; Fridman WH; Debré B; Thiounn N
    J Urol; 1998 Mar; 159(3):1079-84. PubMed ID: 9474235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.
    Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Gonzalez M; Portillo J; Ojea A; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Montesinos M; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA
    J Urol; 2009 Nov; 182(5):2195-203. PubMed ID: 19758621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation.
    Ovesen H; Horn T; Steven K
    J Urol; 1997 May; 157(5):1655-9. PubMed ID: 9112499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
    Kim JC; Steinberg GD
    J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V; Pode D; Pikarsky E; Mandelboim O
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha.
    Esuvaranathan K; Chiong E; Thamboo TP; Chan YH; Kamaraj R; Mahendran R; Teh M
    Cancer; 2007 Mar; 109(6):1097-105. PubMed ID: 17311305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
    Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
    J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer.
    Raj GV; Herr H; Serio AM; Donat SM; Bochner BH; Vickers AJ; Dalbagni G
    J Urol; 2007 Apr; 177(4):1283-6; discussion 1286. PubMed ID: 17382713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.
    Takayama H; Nishimura K; Tsujimura A; Nakai Y; Nakayama M; Aozasa K; Okuyama A; Nonomura N
    J Urol; 2009 Apr; 181(4):1894-900. PubMed ID: 19237175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
    Herr HW
    J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression.
    Thalmann GN; Dewald B; Baggiolini M; Studer UE
    J Urol; 1997 Oct; 158(4):1340-4. PubMed ID: 9302115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer.
    Alvarez-Múgica M; Cebrian V; Fernández-Gómez JM; Fresno F; Escaf S; Sánchez-Carbayo M
    J Urol; 2010 Oct; 184(4):1507-13. PubMed ID: 20723929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.
    Gontero P; Bohle A; Malmstrom PU; O'Donnell MA; Oderda M; Sylvester R; Witjes F
    Eur Urol; 2010 Mar; 57(3):410-29. PubMed ID: 19969411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.